Member Info for BuenaVista

Hmm... I wonder how much of the world you understand... Certainly contribute nothing but stupidity. In the bin you go.

And cj62, to quote more from where yuo quoted:

Participants must have inoperable or metastatic pancreatic, colorectal, non-small cell lung, head and neck, ovarian, breast, bladder, esophageal, prostate, or biliary tract cancer, soft tissue sarcoma, or cancer of unknown primary that continues to grow despite standard treatment.

i.e. all treatments tried, terminally ill, end-of-life

cj62, not true.

Look at slide 81 from Science Day.
https://avacta.com/wp-content/uploads/2023/02/MASTER-DECK-Avacta-Science-Day-23.02.23_compressed-1.pdf

ECOG PS, n (%)
0 (Capable of normal activity)
1 (Restricted in strenuous activity)

What I meant was the patient may have been referred to Dr Tap by a colleague at MSK, or indeed by a clinician from outside MSK, and hence would probably not be a STS patient.

I think this 'referral' method is largely how it works. Otherwise patients could only get on clinical trials that their own oncologist is involved in, which is patently not the case.

Tbf, we don't know that this patient is one of Dr Tap's even if he sees non-STS patients. MSK see all sorts of cancer patients so I think this is likely to be a non-STS patient - these are end-of-life patients and STS patients will mostly have received anthracyclines, so to be a STS patient he/she would have to have had minimal anthracycline or have refused that treatment or to have been newly diagnosed and terminal.

True RD, but if that was the case I doubt AS would then say "Dosing the first patient in the US is a key milestone and reflects the continuing excellent progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole."

When SP is disconnected from value, knowledge is power.

Use it wisely! ;0)

Do NOT ignore the SP.

Fill your boots!!!!!!!!!!

FFS just ignore it

FFS just ignore it

Oh dear. Brand new account Mystic Ianbt has arrived ...in the green bin.

https://www.londonstockexchange.com/news-article/AVCT/first-patient-dosed-in-the-us-in-ava6000-phase-1/15933661

.

What's the matter Daz9643/Clown101? Your Ade1234/Clown101 having a day off?

You do have a point. The clinicians' and the hospitals' services and facilities should be being donated free of charge to Avacta. It's so blindingly stupid, sorry, obvious, I should have thought of that.

In the bin you go with all the other twunts.

LSE staff still reading the bore's posting history. Or rather, still dozed off whilst reading through the bore's posting history. Maybe they'll wake long enough tomorrow to reset the day. Or maybe they'll still be dozing. There is a lot to read...

...And now moniman, whom I now remember from previous times as a troll, goes in the green bin with the others.

moniman, it's a very old bashing ploy to ask whether a tech company will ever make a profit. The answer is obvious: no tech company ever survived without fund raises and no one should think they could.

Not addressed to you, moniman, because you clearly know nothing, and care even less, about Avacta, but to other board members who may read this thread: it is very normal for a company with new tech to be loss making for several years until that tech leads to products that can be sold and are wanted. It is up to you to DYOR and decide for yourselves whether Avacta will be successful rather than just being scared by this tired and mindless "will they ever make a profit" rubbish from people looking for a lower SP entry by trying to scare people into selling.

Fantastic news HurstBot!

I'm reading discontent at delays in the prime fillet cooking event and the US listing. Some of that may be genuine anguish, some just another opportunity to bash the stock (every stock and every bulletin board has these vermin), but anyone who has spent any time invested in small tech companies that are trying to bring groundbreaking products to market will know that delay is a common feature of such ventures.

And the reasons are two-fold.

Firstly, the S-curve - if you don't know what that is Google it! All industries and all products go through this. It is an unavoidable consequence of doing something new.

The second reason is that it is particularly difficult to start up the S-curve when the product is novel and in a nascent sector that hasn't quite been accepted as the future direction of the industry.

Of course, it may, just may, at the end of the day, be that farmed animal meat is the future...

The problem is that it is all so new. No one has been there already and mapped out the landscape. This doesn't matter so much for a large company as it survives on sales and it can afford the investment in new areas to take time as the research, development and marketing are financed by the company's regular business. Of course something is expected at the end of all the RD&M as the company needs to move to the next S-curve to survive longterm. But for small companies the need is more urgent as the cash reserves will run down and this gives the bashers - traders and paid trolls - the opportunity to spread fear, uncertainty and doubt (aka FUD). And one of their 'concerns' that they love to express is the inactivity and delays that the company is experiencing. Just remember that, to misquote Count Arthur Strong out of context, when Hillary Edmund set off to climb the Arger he didn't turn round to Shepherd Tenpin as he was leaving and say "Put the kettle on lad, I'll be back in ten minutes." When exploring new terrain the unknown will, necessarily, involve unforeseen events and consequent delays.